Further research with larger cohorts of patients is warranted, and it is vital to determine whether serum exosomal PD-L1 and tumor PD-L1 status or other blood biomarkers can be used as a more accurate method for predicting the efficacy of anti-PD-1/PD-L1 therapies. This evidence concerns the gene PDCD1 and neoplasm.